FINAL RESULTS OF PHASE II RANDOMIZED TRIAL OF AZACITIDINE VERSUS SUPPORT TREATMENT IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME WITHOUT THE 5Q DELETION

被引：1
|
作者：
Sanchez-Garcia, J. [1 ]
Falantes, J. [2 ]
Medina, A. [3 ]
Hernandez-Mohedo, F. [4 ]
Torres-Sabariego, A. [5 ]
Bailen, A. [6 ]
Sole, M.
Casano, J. [1 ]
Calderon, C.
Hermosin, L. [7 ]
Vahi, M. [5 ]
Serrano, J. [1 ]
机构：
[1] Univ Cordoba, Hematol, Reina Sofia Hosp, IMIBIC, Cordoba, Spain
[2] Univ Hosp Virgen Rocio, Hematol, Seville, Spain
[3] Hosp Costa Sol, Hematol, Marbella, Spain
[4] Hosp Costa Sol, Hematol, Granada, Spain
[5] Hosp Virgen Valme, Hematol, Seville, Spain
[6] Hosp Univ Carlos Haya, Hematol, Malaga, Spain
[7] Hosp Jerez, Hematol, Jerez de la Frontera, Spain
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30115-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
114
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] Interim analysis of phase II randomized trial of azacitidine versus support treatment in patients with low-risk myelodysplastic syndrome
    Sanchez-Garcia, J.
    Falantes, J.
    Medina, A.
    Hernandez-Mohedo, F.
    Torres-Sabariego, A.
    Hermosin, L.
    Bailen, A.
    Sole, M.
    Casano, J.
    Calderon, C.
    Vahi, M.
    Serrano, J.
    LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
  • [2] Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 1195 - 1195
  • [3] Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia
    Sanchez-Garcia, Joaquin
    Falantes, Jose
    Medina Perez, Angeles
    Hernandez-Mohedo, Francisca
    Hermosin, Lourdes
    Torres-Sabariego, Angeles
    Bailen, Alicia
    Hernandez-Sanchez, Jesus M.
    Sole Rodriguez, Maria
    Javier Casano, Francisco
    Calderon, Cristina
    Labrador, Maria
    Vahi, Maria
    Serrano, Josefina
    Lumbreras, Eva
    Maria Hernandez-Rivas, Jesus
    LEUKEMIA & LYMPHOMA, 2018, 59 (05) : 1095 - 1104
  • [4] Part 3: Myelodysplastic syndromes-Treatment of low-risk patients without the 5q deletion
    Rodrigues Pereira Velloso, Elvira Deolinda
    Meira Magalhaes, Silvia Maria
    Lopes Ferrari Chauffaille, Maria de Lourdes
    Buzzini, Renata
    Bernardo, Wanderley Marques
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) : 267 - 273
  • [5] Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion
    Yang, Yan
    Gao, Sujun
    Fan, Hongqiong
    Lin, Hai
    Li, Wei
    Wang, Juan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (03) : 803 - 807
  • [6] Part 4: Myelodysplastic syndromes-Treatment of low-risk patients with the 5q deletion
    Meira Magalhaes, Silvia Maria
    Pereira Velloso, Elvira Deolinda Rodrigues
    Buzzini, Renata
    Bernardo, Wanderley Marques
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) : 274 - 277
  • [7] Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Schmidt, Aline
    Visanica, Sorin
    Eclache, Virginie
    Turlure, Pascal
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Rea, Delphine
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2011, 35 (11) : 1444 - 1448
  • [8] Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
    Almeida, Antonio
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Goldberg, Stuart L.
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2135 - 2143
  • [9] Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
    Baron, Frederic
    Suciu, Stefan
    Amadori, Sergio
    Muus, Petra
    Zwierzina, Heinz
    Denzlinger, Claudio
    Delforge, Michel
    Thyss, Antoine
    Selleslag, Dominik
    Indrak, Karel
    Ossenkoppele, Gert
    de Witte, Theo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04): : 529 - 533
  • [10] “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
    Bengt Rasmussen
    Gudrun Göhring
    Elsa Bernard
    Lars Nilsson
    Magnus Tobiasson
    Martin Jädersten
    Hege Garelius
    Ingunn Dybedal
    Kirsten Grønbaek
    Elisabeth Ejerblad
    Fryderyk Lorenz
    Max Flogegård
    Claus Werenberg Marcher
    Annette Öster Fernström
    Lucia Cavelier
    Elli Papaemmanuil
    Freja Ebeling
    Astrid Olsnes Kittang
    Jan Maxwell Nørgaard
    Leonie Saft
    Lars Möllgård
    Eva Hellström-Lindberg
    Leukemia, 2022, 36 : 1436 - 1439
12345